<SEC-DOCUMENT>0001193125-21-120458.txt : 20210419
<SEC-HEADER>0001193125-21-120458.hdr.sgml : 20210419
<ACCEPTANCE-DATETIME>20210419090054
ACCESSION NUMBER:		0001193125-21-120458
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20210419
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210419
DATE AS OF CHANGE:		20210419

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MIMEDX GROUP, INC.
		CENTRAL INDEX KEY:			0001376339
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				262792552
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35887
		FILM NUMBER:		21833357

	BUSINESS ADDRESS:	
		STREET 1:		1775 W OAK COMMONS COURT, NE
		CITY:			MARIETTA
		STATE:			GA
		ZIP:			30062
		BUSINESS PHONE:		(770) 651-9100

	MAIL ADDRESS:	
		STREET 1:		1775 W OAK COMMONS COURT, NE
		CITY:			MARIETTA
		STATE:			GA
		ZIP:			30062

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Alynx, Co.
		DATE OF NAME CHANGE:	20060922
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d95836d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mdxg="http://mimedx.com/20210419" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body>
 <div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityAddressAddressLine1_duration_2021-04-19_to_2021-04-19" name="dei:EntityAddressAddressLine1" contextRef="duration_2021-04-19_to_2021-04-19">1775 W OAK COMMONS COURT</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2021-04-19_to_2021-04-19">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2021-04-19_to_2021-04-19">0001376339</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="mdxg-20210419.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2021-04-19_to_2021-04-19"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-19</xbrli:startDate> <xbrli:endDate>2021-04-19</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, DC 20549</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2021-04-19_to_2021-04-19">8-K</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">PURSUANT TO SECTION 13 OR 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">OF THE SECURITIES EXCHANGE ACT OF 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2021-04-19_to_2021-04-19" format="ixt:datemonthdayyearen">April 19, 2021</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2021-04-19_to_2021-04-19">MIMEDX GROUP, INC.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in charter)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2021-04-19_to_2021-04-19" format="ixt-sec:stateprovnameen">Florida</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2021-04-19_to_2021-04-19">001-35887</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2021-04-19_to_2021-04-19">26-2792552</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">1775 West Oak Commons Ct., <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2021-04-19_to_2021-04-19">NE</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2021-04-19_to_2021-04-19">Marietta</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2021-04-19_to_2021-04-19">GA</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2021-04-19_to_2021-04-19">30062</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of principal executive offices) (Zip Code)</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2021-04-19_to_2021-04-19">(770)</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2021-04-19_to_2021-04-19">651-9100</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2021-04-19_to_2021-04-19" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2021-04-19_to_2021-04-19" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2021-04-19_to_2021-04-19" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2021-04-19_to_2021-04-19" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section 12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2021-04-19_to_2021-04-19">Common Stock, $0.001 par value per share</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2021-04-19_to_2021-04-19">MDXG</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2021-04-19_to_2021-04-19" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#160;&#160;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2021-04-19_to_2021-04-19" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#9744;</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Important Cautionary Statement </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The press release referenced below includes forward-looking statements. Statements regarding: (i)&#160;expectations about the results of clinical trials, including expectations regarding safety and efficacy, and the value of safety data from the trials; (ii)&#160;the Company&#8217;s expectations regarding mdHACM&#8217;s potential use as a safe and effective treatment option, and that it may be an effective treatment for persons battling inflammatory conditions; (iii)&#160;the Company&#8217;s plans to review and analyze the results of its plantar fasciitis, Achilles tendonitis, and knee osteoarthritis clinical trials, and to announce <span style="white-space:nowrap">top-line</span> data from the plantar fasciitis, Achilles tendonitis, and knee osteoarthritis clinical trials in Q3 2021; (iv) plans for meetings with the FDA, and planned BLA submissions to the FDA, and their timing; and (v)&#160;plans for future clinical trials, and their timing; are forward looking statements. Additional forward-looking statements may be identified by words such as &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;will,&#8221; &#8220;preliminary,&#8221; and similar expressions, and are based on management&#8217;s current beliefs and expectations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-looking statements. Factors that could cause actual results to differ from expectations include: (i)&#160;the results of a clinical trial or trials may not demonstrate that the product is safe or effective, or may have little or no statistical value; (ii)&#160;the Company may change its plans due to unforeseen circumstances, and delay or alter the timeline for future trials, analyses, or public announcements; (iii)&#160;the timing of any meeting with the FDA depends on successful clinical trial results and is outside of the Company&#8217;s control; (iv)&#160;a BLA submission requires a number of prerequisites, including favorable study results and statistical support, and completion of a satisfactory FDA inspection of the Company&#8217;s manufacturing facility or facilities; and (v)&#160;plans for future clinical trials depend on the results of pending clinical trials. The Company describes additional risks and uncertainties in the Risk Factors section of its most recent annual report and quarterly reports filed with the Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and the Company assumes no obligation to update any forward-looking statement. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;7.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Regulation FD. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&#160;19, 2021, MiMedx Group Inc., (the &#8220;Company&#8221;) issued a press release announcing that the last patients had completed their last visits in all three of the Company&#8217;s late-stage clinical trials of micronized dehydrated Human Amnion Chorion Membrane (mdHACM). A copy of the press release is attached hereto as exhibit 99.1 and is incorporated herein by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td style="width:93%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom" align="center"><span style="font-weight:bold">Exhibit<br />No.</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">Description of Exhibit</span></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d95836dex991.htm">Press release dated April&#160;19, 2021. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">The cover page from this Current Report on Form <span style="white-space:nowrap">8-K,</span> formatted in Inline XBRL.</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Exchange Act, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:3%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:45%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">MIMEDX GROUP, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Date: April&#160;19, 2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Peter M. Carlson</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Peter M. Carlson</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</p></td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d95836dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Exhibit 99.1 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MiMedx Announces Last Patients Last Visits in Three Late-Stage Musculoskeletal Trials with Proprietary Tissue Technology </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Advances Potential for Use of Micronized Dehydrated Human Amnion Chorion Membrane (mdHACM) as a Safe and Effective Treatment Option </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>On Track to Advance Planned Analyses and Announce <FONT STYLE="white-space:nowrap">Top-Line</FONT> Data in Plantar Fasciitis, Achilles
Tendonitis and Knee Osteoarthritis in Q3 2021 </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MARIETTA, Ga., April 19, 2021</B> &#151; MiMedx Group, Inc. (Nasdaq: MDXG) (&#147;MiMedx&#148; or
the &#147;Company&#148;), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced that the last patients have completed their last clinical visits in two late-stage Investigational New Drug (IND)
trials: Phase 3 studies of AmnioFix<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Injectable (micronized dehydrated Human Amnion Chorion Membrane (mdHACM)) as a potential treatment for Plantar Fasciitis and Achilles Tendonitis. In
addition, all clinical effectiveness endpoint visits have been completed in a Phase 2B study of mdHACM as a potential treatment for Knee Osteoarthritis. With the completion of these patient visits, the Company will begin the planned review and
statistical analyses of data from all three trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Completion of the Phase 2B study for mdHACM as a treatment for Knee Osteoarthritis marks an
extraordinary milestone,&#148; said Alfred Gellhorn, M.D., Adjunct Associate Professor of Clinical Rehabilitation and Director of Sports Medicine, Weill Cornell Medicine. &#147;There is a tremendous unmet need for safe and effective treatment
options for Knee Osteoarthritis. The osteoarthritis community has long recognized that current treatment options are painfully insufficient.&nbsp;The benefit of a novel therapeutic option in this setting for both patients and clinicians cannot be
overstated.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;These studies are designed to prove the clinical efficacy and safety of AmnioFix Injectable in treating frustrating chronic
conditions,&#148; said Stuart Miller, M.D., Principal Investigator, Department of Orthopaedic Surgery, MedStar Union Memorial Hospital, and Assistant Professor, Department of Orthopaedic Surgery, Johns Hopkins University School of Medicine,
Baltimore, Maryland. &#147;The prior Phase 2B Plantar Fasciitis study has helped establish the product&#146;s safety profile, and I believe these further studies may demonstrate its effectiveness in battling inflammatory conditions. As a physician
committed to advancing patient care, I would welcome having additional treatment options that could potentially address the pain and quality of life issues my patients face on a daily basis.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Timothy R. Wright, MiMedx Chief Executive Officer, added, &#147;These trials play key roles in our late-stage AmnioFix Injectable pipeline, and with last
patient visits complete across the three trials, we will now lock the databases, conduct the appropriate statistical analyses, and request meetings with the U.S. Food and Drug Administration (FDA) to review the findings. We anticipate announcing
top-line results of all three trials this summer, have commenced planning efforts to initiate our Phase 3 clinical trial for Knee Osteoarthritis, and plan to file a Biologics License Application (BLA) for Plantar Fasciitis in the first half of 2022.
Although we do not anticipate pursuing a BLA for Achilles Tendonitis, we expect to glean valuable safety data for the AmnioFix Injectable product from that trial. On behalf of MiMedx, I would like to express our sincere gratitude to all the
patients, families and physicians who participated in these important studies critical to our submissions to FDA for approvals for the therapeutic use of amniotic tissues.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The typical steps for obtaining FDA approval of a BLA to market a biological product in the United States include performance of two adequate and
well-controlled clinical trials in accordance with Good Clinical Practices to establish the safety and efficacy of the product for each indication, along with the development of purity, potency and identity tests to demonstrate consistency and
reliability of the manufacturing process through a chemistry, </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">manufacturing and control program. Submission to the FDA of a BLA for marketing the product includes, among
other things, reports of the outcomes and full data sets of the clinical trials, and proposed labeling and packaging for the product. In addition, the satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which
the product is produced is required to assess compliance with FDA&#146;s Current Good Manufacturing Practice (CGMP) regulations, to assure that the facilities, methods and controls are adequate to ensure the product&#146;s identity, potency, quality
and purity. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About the <U>Micronized dHACM vs. Saline in the Treatment of Osteoarthritis of the Knee</U> Trial </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This trial, the first randomized clinical study of a micronized dehydrated Human Amnion/Chorion Membrane (mdHACM) Injection in the Treatment of Knee
Osteoarthritis (KOA), is a Phase 2B, prospective, double-blinded, randomized controlled trial of the mdHACM injection as compared to saline placebo injection in the treatment of osteoarthritis of the knee. Trial enrollment was planned to include 466
patients between the ages of 21 to 80 years, with a diagnosis of osteoarthritis defined as grade 1 to 3 on the Kellgren Lawrence grading scale and a Visual Analog Scale (VAS) for Pain score greater than 45. Due to a lower-than-expected number of
study participant dropouts, and with an adequate number of patients meeting the required time in study to assess the primary endpoint, the final number randomized will be 447 patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The primary efficacy endpoints include change from baseline in VAS at 90 days, change from baseline in Western Ontario and McMaster Universities (WOMAC)
Osteoarthritis Index at 90 days, and incidence of related Adverse Events (AEs), Serious Adverse Events (SAEs), and Unanticipated Adverse Events at 365 days. Secondary endpoints include: change from baseline in VAS at 180 days and change from
baseline in WOMAC at 180 days. The WOMAC Index has become a standard study metric in KOA studies and its use has been extensively validated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The blinded
efficacy visits for this study are complete, with the <FONT STYLE="white-space:nowrap">12-month</FONT> safety visit follow up as requested by FDA scheduled to compete in October 2021. The Company intends to initiate a Phase 3 study of mdHACM
injection in the treatment of Knee Osteoarthritis in Q3 2021, after an end of Phase 2 meeting with FDA, and planning for this effort is underway. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Knee Osteoarthritis </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Osteoarthritis (OA) is by far
the most common joint disease &#150; millions of adults experience pain and decreased quality of life every day because of joint destruction caused by osteoarthritis. Osteoarthritis is responsible for a staggering public health and economic impact:
more than 242&nbsp;million people worldwide currently suffer from symptomatic OA of the knee and hip; 45% of all people have a lifetime risk of developing OA of the knee; and OA is responsible for $71&nbsp;billion in lost earnings annually in the
U.S. Although knee replacement is an option for those with advanced knee arthritis, it carries significant risks, and current treatment algorithm, including oral anti-inflammatory medications, cortisone injections, and hyaluronic acid injections,
are limited in the amount of relief it can provide. Anti-inflammatories have negative cardiovascular effects and injected steroids cause further joint degeneration. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About the <U>Micronized dHACM Injectable for the Treatment of&nbsp;Plantar Fasciitis</U> Trial </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This study is a Phase 3, prospective, double-blinded, randomized controlled trial of micronized dehydrated Human Amnion Chorion Membrane (mdHACM) injection as
compared to saline placebo injection in the treatment of plantar fasciitis. The trial enrolled 277 patients between the ages of 21 and 79 years, with an investigator-confirmed diagnosis of plantar fasciitis for greater than or equal to one month (30
days) and less than or equal to 18 months. Patients were required to have a Visual Analog Scale (VAS) Pain scale of greater than or equal to 45 mm at randomization and be receiving conservative treatment for greater than or equal to 1 month (30
days), including any of the following modalities: Rest, Ice, Compression, Elevation (RICE); stretching exercises; NSAIDs or orthotics. The primary endpoints are change in VAS for Pain at 90 Days and incidence of related adverse events at 180 days,
serious adverse events and unanticipated events during the first 12 months post-injection. Secondary endpoints include self-reported responses to the Foot Function Index &#150; Revised <FONT STYLE="white-space:nowrap">(FFI-R)</FONT> at 90 days. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This study follows a Phase 2B prospective, <FONT STYLE="white-space:nowrap">single-blinded,</FONT>
randomized controlled trial of 145 patients, which demonstrated a statistically significant reduction in VAS score for pain and an improvement in Foot Function Index-Revised <FONT STYLE="white-space:nowrap">(FFI-R)</FONT> score. At the <FONT
STYLE="white-space:nowrap">3-month</FONT> <FONT STYLE="white-space:nowrap">follow-up,</FONT> the mean VAS score was reduced by 76% for patients in the Treatment Group compared with a 45% reduction for the Control Group (p&lt;0.0001), and the mean <FONT
STYLE="white-space:nowrap">FFI-R</FONT> score was reduced by 60% for patients in the Treatment Group, while the Control Group had mean reduction of 40% versus baseline (p=0.0004). Overall, at the <FONT STYLE="white-space:nowrap">three-month</FONT>
study <FONT STYLE="white-space:nowrap">follow-up</FONT> visit, 60 (82.2%) patients in the treatment group, and 34 (47.2%) patients in the control group reported at least a 50% reduction in VAS score from baseline (p&lt;0.0001). These effectiveness
results were maintained at the <FONT STYLE="white-space:nowrap">six-month</FONT> secondary endpoint. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Plantar Fasciitis </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">More than two million people are treated for plantar fasciitis inflammation in the United States annually. In 10% of patients treated with traditional
measures, the condition progresses to chronic plantar fasciitis-related pain &#150; recovery from which is lengthy and recurrence of which is very common, with an estimated $284&nbsp;million annual national economic burden. The current treatment
algorithm aims to maintain arch shape, modify foot loading and/or improve shock absorbency of the heel through night splints and orthotics. While these measures may assist in reducing pain associated with plantar fasciitis, they do not address the
root cause of the condition, which is thought to be both degenerative and inflammatory. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About the <U>Micronized dHACM Injectable for the Treatment of
Achilles Tendonitis</U> Trial </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This study is a Phase 3, prospective, double-blinded, randomized controlled trial of micronized dehydrated Human Amnion
Chorion Membrane (mdHACM) injection as compared to saline placebo injection in the treatment of Achilles Tendonitis. The trial enrolled 158 patients between the ages of 21 and 80 years, with an investigator-confirmed diagnosis of plantar fasciitis
for greater than or equal to 1 month (30 days) and less than or equal to 18 months. Patients were required to have a Visual Analog Scale (VAS) Pain scale of greater than or equal to 45 mm at randomization and be receiving conservative treatment for
greater than or equal to one month (30 days), including any of the following modalities: Rest, Ice, Compression, Elevation (RICE); stretching exercises; NSAIDs or orthotics. The primary endpoints are change in VAS for Pain at 90 Days and incidence
of related adverse events at 180 days, serious adverse events and unanticipated events during the first 12 months post-injection. Secondary endpoints include self-reported responses to the Foot Function Index &#150; Revised <FONT
STYLE="white-space:nowrap">(FFI-R)</FONT> at 90 days. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company does not anticipate pursuing a BLA for Achilles Tendonitis at this time, and plans to
review options for this program after assessing the results of the Phase 3 study, including potentially exploring the efficacy of AmnioFix Injectable in a more well-defined subset of patients. The Company does expect to glean valuable safety data
from the trial for the AmnioFix Injectable product, which can be used to supplement the data package for other clinical indications underway and inform future clinical indications under consideration. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Achilles Tendonitis </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Achilles tendonitis is a
common condition that can occur at any time, but often results from years of overuse (long distance runners, sprinters) and is not typically related to a specific injury. Achilles tendonitis can result in pain and stiffness along the Achilles
tendon; pain along the tendon or back of the heel that worsens with activity; severe pain the day after exercising; thickening of the tendon; bone spurs (insertional tendinitis); and chronic swelling. All may result in limited mobility and,
potentially, a rupture or tear in the Achilles tendon. Current treatments include rest, icing, NSAIDs; exercise; orthotics; cortisone injections; and surgery. Moderate to severe post-surgical pain is noted in 20% to 30% of patients and is the most
common complication. In addition, wound infection can occur, which is difficult to treat in this location. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Important Cautionary Statement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release includes forward-looking statements. Statements regarding: (i)&nbsp;expectations about the results of clinical trials, including
expectations regarding safety and efficacy, and the value of safety data from the trials; (ii)&nbsp;the Company&#146;s expectations regarding mdHACM&#146;s potential use as a safe and effective treatment option, and that it may be an effective
treatment for persons battling inflammatory conditions; (iii)&nbsp;the Company&#146;s plans to review and analyze the results of its plantar fasciitis, Achilles tendonitis, and knee osteoarthritis clinical trials, and to announce <FONT
STYLE="white-space:nowrap">top-line</FONT> data from the plantar fasciitis, Achilles tendonitis, and knee osteoarthritis clinical trials in Q3 2021; (iv) plans for meetings with the FDA, and planned BLA submissions to the FDA, and their timing; and
(v)&nbsp;plans for future clinical trials, and their timing; are forward looking statements. Additional forward-looking statements may be identified by words such as &#147;believe,&#148; &#147;expect,&#148; &#147;may,&#148; &#147;plan,&#148;
&#147;potential,&#148; &#147;will,&#148; &#147;preliminary,&#148; and similar expressions, and are based on management&#146;s current beliefs and expectations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements.
Actual results may differ materially from those set forth in the forward-looking statements. Factors that could cause actual results to differ from expectations include: (i)&nbsp;the results of a clinical trial or trials may not demonstrate that the
product is safe or effective, or may have little or no statistical value; (ii)&nbsp;the Company may change its plans due to unforeseen circumstances, and delay or alter the timeline for future trials, analyses, or public announcements;
(iii)&nbsp;the timing of any meeting with the FDA depends on successful clinical trial results and is outside of the Company&#146;s control; (iv)&nbsp;a BLA submission requires a number of prerequisites, including favorable study results and
statistical support, and completion of a satisfactory FDA inspection of the Company&#146;s manufacturing facility or facilities; and (v)&nbsp;plans for future clinical trials depend on the results of pending clinical trials. The Company describes
additional risks and uncertainties in the Risk Factors section of its most recent annual report and quarterly reports filed with the Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release
and the Company assumes no obligation to update any forward-looking statement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Important Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company intends to file a definitive proxy statement and associated WHITE proxy card in connection with the solicitation of proxies for the 2021 Annual
Meeting with the Securities and Exchange Commission (the &#147;SEC&#148;). Details concerning the nominees of the Company&#146;s board of directors for election at the 2021 Annual Meeting will be included in the proxy statement. BEFORE MAKING ANY
VOTING DECISION, SHAREHOLDERS OF THE COMPANY ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH OR FURNISHED TO THE SEC, INCLUDING THE COMPANY&#146;S DEFINITIVE PROXY STATEMENT AND ANY SUPPLEMENTS THERETO, BECAUSE THEY WILL CONTAIN IMPORTANT
INFORMATION. Investors and shareholders will be able to obtain a copy of the definitive proxy statement and other documents filed by the Company free of charge from the SEC&#146;s website at www.sec.gov. The Company&#146;s shareholders will also be
able to obtain, without charge, a copy of the definitive proxy statement and other relevant filed documents from the &#147;SEC Filings&#148; section of the Company&#146;s website at <U>www.mimedx.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Participants in the Solicitation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company, its
directors, its director nominees and certain of its executive officers are participants in the solicitation of proxies from shareholders in respect of the 2021 Annual Meeting. Information regarding the names of the Company&#146;s directors and
executive officers and certain other individuals and their respective interests in the Company by security holdings or otherwise is set forth in the Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> of the Company for the fiscal
year ended December&nbsp;31, 2020, filed with the SEC on March&nbsp;8, 2021, and the Company&#146;s definitive proxy statement for the 2020 annual meeting of the Company&#146;s shareholders, filed with the SEC on October&nbsp;15, 2020. To the extent
holdings of such participants in the Company&#146;s securities have changed since the amounts described in the proxy statement for the 2020 annual meeting of the Company&#146;s shareholders, such changes have been reflected on Initial Statements of
Beneficial Ownership on Form 3 or Statements of Change in Ownership on Form 4 filed with the SEC. Additional information regarding the interests of these participants in any proxy solicitation and a </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
description of their direct and indirect interests, by security holdings or otherwise, will also be included in the Company&#146;s proxy statement and other relevant materials to be filed with
the SEC, if and when they become available. Details regarding the nominees of the Company&#146;s Board of Directors for election at the 2021 Annual Meeting will be included in the Company&#146;s proxy statement, when available. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About MiMedx </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MiMedx is an industry leader in utilizing
amniotic tissue as a platform for regenerative medicine, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental biologics, we have both a
core business, focused on addressing the needs of patients with acute and chronic <FONT STYLE="white-space:nowrap">non-healing</FONT> wounds, and a promising late-stage pipeline targeted at decreasing pain and improving function for patients with
degenerative musculoskeletal conditions. We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> process. We employ
Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts. MiMedx has supplied over two million allografts, through both direct and consignment shipments. For additional information,
please visit <U>www.mimedx.com</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jack
Howarth </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investor Relations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">404-360-5681</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>investorrelations@mimedx.com </U></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>mdxg-20210419.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-7 Build:20201110.1 -->
<!-- Creation date: 4/19/2021 4:56:25 PM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2019-01-31"
  xmlns:mdxg="http://mimedx.com/20210419"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://mimedx.com/20210419"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2019-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2011-01-31" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mdxg-20210419_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mdxg-20210419_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://mimedx.com//20210419/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>mdxg-20210419_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-7 Build:20201110.1 -->
<!-- Creation date: 4/19/2021 4:56:25 PM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>mdxg-20210419_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-7 Build:20201110.1 -->
<!-- Creation date: 4/19/2021 4:56:25 PM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://mimedx.com//20210419/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="mdxg-20210419.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://mimedx.com//20210419/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>d95836d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mdxg-20210419.xsd" xlink:type="simple"/>
    <context id="duration_2021-04-19_to_2021-04-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
        </entity>
        <period>
            <startDate>2021-04-19</startDate>
            <endDate>2021-04-19</endDate>
        </period>
    </context>
    <dei:EntityAddressAddressLine1
      contextRef="duration_2021-04-19_to_2021-04-19"
      id="Hidden_dei_EntityAddressAddressLine1_duration_2021-04-19_to_2021-04-19">1775 W OAK COMMONS COURT</dei:EntityAddressAddressLine1>
    <dei:AmendmentFlag contextRef="duration_2021-04-19_to_2021-04-19">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2021-04-19_to_2021-04-19"
      id="Hidden_dei_EntityCentralIndexKey">0001376339</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2021-04-19_to_2021-04-19">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2021-04-19_to_2021-04-19">2021-04-19</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2021-04-19_to_2021-04-19">MIMEDX GROUP, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2021-04-19_to_2021-04-19">FL</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2021-04-19_to_2021-04-19">001-35887</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2021-04-19_to_2021-04-19">26-2792552</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine2 contextRef="duration_2021-04-19_to_2021-04-19">NE</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2021-04-19_to_2021-04-19">Marietta</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2021-04-19_to_2021-04-19">GA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2021-04-19_to_2021-04-19">30062</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2021-04-19_to_2021-04-19">(770)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2021-04-19_to_2021-04-19">651-9100</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2021-04-19_to_2021-04-19">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2021-04-19_to_2021-04-19">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2021-04-19_to_2021-04-19">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2021-04-19_to_2021-04-19">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2021-04-19_to_2021-04-19">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2021-04-19_to_2021-04-19">MDXG</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2021-04-19_to_2021-04-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2021-04-19_to_2021-04-19">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139953619168952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Apr. 19, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1775 W OAK COMMONS COURT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001376339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr. 19,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MIMEDX GROUP, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">FL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35887<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-2792552<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">NE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Marietta<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">GA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">30062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(770)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">651-9100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDXG<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MXNQVPQF4@7T!?E]):0X->RK._ZG1^PM02P,$%     @ &DB34I^@&_"Q @
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M\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @
M&DB34I>*NQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q ?\70GC '
MT"&(,V7Q%@3Y 5:B#]@2!8I%G;^OVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2
M:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y +AEFM[UD%J=SI%>(7->=
MI3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8
M%II%R=.B':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+
M P04    "  :2)-2'#AEZC\!   \ @  #P   'AL+W=O<FMB;V]K+GAM;(U1
MRV["0 S\E=5^0!-0BU1$N)0^D*H6E8K[DG6(Q3XBKP,M7U\G452D7GKR>FR-
M9V87YTC'?8Q']>5=2(6NF9MYEJ6R!F_236P@R*2*Y U+2X<L-03&IAJ O<NF
M>3[+O,&@EXN1:T/9=1,92L88!.R '<(Y_<Z[5ITPX1X=\G>A^[<#K3P&]'@!
M6^A<JU3'\TLDO,3 QFU+BLX5>C(,=D",Y1]XVXG\-/O4(VSV'T:$%'J6"V&%
ME+C?Z/F-:#R!+ ]=R_$)'0.M#,,SQ;;!<.AHQ$5V9://8:Q#B'/Z3XRQJK"$
M52Q;#X&'' E<)S"D&IND53 >"CVN*!.L>@PL(:EU&*ADMW,JI]=V<,TB]RI#
MFJ,,:&T'X:-:"Q4&L&]R( DNR94;4EWI>::W=Y-[2:AU[D&P]_ :C1W-CQ^W
M_ %02P,$%     @ &DB34B0>FZ*M    ^ $  !H   !X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<[61/0Z#, R%KQ+E #50J4,%3%U8*RX0!?,C$A+%K@JW
M+X4!D#IT8;*>+7_OR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB
M688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\7>BI160I2A4:
MY$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?
M#'!X=/X!4$L#!!0    ( !I(DU)ED'F2&0$  ,\#   3    6T-O;G1E;G1?
M5'EP97-=+GAM;*V334[#,!"%KQ)E6R4N+%B@IAM@"UUP 6-/&JO^DV=:TMLS
M3MI*H!(5A4VL>-Z\SYZ7K-Z/$;#HG?78E!U1?!0"50=.8ATB>*ZT(3E)_)JV
M(DJUDUL0]\OE@U#!$WBJ*'N4Z]4SM')OJ7CI>1M-\$V9P&)9/(W"S&I*&:,U
M2A+7Q<'K'Y3J1*BY<]!@9R(N6%"*JX1<^1UPZGL[0$I&0[&1B5ZE8Y7HK4 Z
M6L!ZVN+*&4/;&@4ZJ+WCEAIC JFQ R!GZ]%T,4TFGC",S[O9_,%F"LC*30H1
M.;$$?\>=(\G=560C2&2FKW@ALO7L^T%.6X.^D<WC_0QI-^2!8ECFS_A[QA?_
M&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ &DB34@=!36*!
ML0   !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M    "  :2)-2NW"N^.X    K @  $0              @ &O    9&]C4')O
M<',O8V]R92YX;6Q02P$"% ,4    "  :2)-2F5R<(Q &  "<)P  $P
M        @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( !I(
MDU+CVSKN3P0  . 0   8              " @0T(  !X;"]W;W)K<VAE971S
M+W-H965T,2YX;6Q02P$"% ,4    "  :2)-2GZ ;\+$"  #B#   #0
M        @ &2#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( !I(DU*7BKL<
MP    !,"   +              "  6X/  !?<F5L<R\N<F5L<U!+ 0(4 Q0
M   ( !I(DU(<.&7J/P$  #P"   /              "  5<0  !X;"]W;W)K
M8F]O:RYX;6Q02P$"% ,4    "  :2)-2)!Z;HJT   #X 0  &@
M    @ '#$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M"  :2)-299!YDAD!  #/ P  $P              @ &H$@  6T-O;G1E;G1?
@5'EP97-=+GAM;%!+!08     "0 ) #X"  #R$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d95836d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com//20210419/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d95836d8k.htm">d95836d8k.htm</File>
    <File>d95836dex991.htm</File>
    <File>mdxg-20210419.xsd</File>
    <File>mdxg-20210419_lab.xml</File>
    <File>mdxg-20210419_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d95836d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d95836d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mdxg-20210419_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mdxg-20210419_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "mdxg-20210419.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "mdxg",
   "nsuri": "http://mimedx.com/20210419",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d95836d8k.htm",
      "contextRef": "duration_2021-04-19_to_2021-04-19",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://mimedx.com//20210419/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d95836d8k.htm",
      "contextRef": "duration_2021-04-19_to_2021-04-19",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://mimedx.com//20210419/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://mimedx.com//20210419/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://mimedx.com//20210419/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://mimedx.com//20210419/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://mimedx.com//20210419/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://mimedx.com//20210419/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://mimedx.com//20210419/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://mimedx.com//20210419/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://mimedx.com//20210419/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://mimedx.com//20210419/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://mimedx.com//20210419/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://mimedx.com//20210419/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://mimedx.com//20210419/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://mimedx.com//20210419/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://mimedx.com//20210419/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://mimedx.com//20210419/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://mimedx.com//20210419/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://mimedx.com//20210419/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://mimedx.com//20210419/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://mimedx.com//20210419/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://mimedx.com//20210419/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://mimedx.com//20210419/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://mimedx.com//20210419/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001193125-21-120458-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-21-120458-xbrl.zip
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MCQ@)\<67(94++TG]1<\PQ#!CM7SS/:'3K^<_"",2P4E\S><<95QPVQ$'DL-
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M%@HG/=4&\&LEJIB9V4!9I4VI?6$-_KZ,:W:V>F&0>)"FWX :H[!<W5D*47'
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M'0  ^V,  !    !D.34X,S9D97@Y.3$N:'1M[5UI<QO)D?V."/R'"GDU04:
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MJ4Y>[%[&R=J1C<S.*WIS5^WK7).<T+#@NSK0V<C:W&8=U1M-;1B:K-VZ-%$
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M$^$E=@F<4CL)H$Z"X<F&<9K%!UD/5Q;SV1)38J"*><B0#TMZF U[J@472\U
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MM^!68Q=P/5'[(U?,GL:UMUVJN@8FZQW<WO0[O;EJ)@U^_@!02P,$%     @
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M(Q'?%-(&@8Z /5P2/V!H _(!422H\RA0Z+\L#T!%@FM&K"%W7$85^*?7@M$
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MV]^\U>-X?/Q"^9R'ZC)\3O6&Y;EOM9B=F+I:ST%].]$2/]YP+='NZ/I6E!E
M,K="X\9HR P_^G%SWZZZ]/:U.EJ^55Z&BMH7] :K;"2/O@WN&%67TXY0!\FW
MVHJ;;C?+9$K%!$[Y+;#<MKK(RO4Z<G[64&XR4!.<A[\IN3!37/=G5)SXGLL!
M%]7E^*QLA_-_**-<17NIN<,&^_+M^HS]9U\EQ99_ 5!+ 0(4 Q0    ( !I(
MDU(_6 -J-Q(  #UH   -              "  0    !D.34X,S9D.&LN:'1M
M4$L! A0#%     @ &DB34K-J,:C<'0  ^V,  !               ( !8A(
M &0Y-3@S-F1E>#DY,2YH=&U02P$"% ,4    "  :2)-2Y0.Y"&,#   4#
M$0              @ %L,   ;61X9RTR,#(Q,#0Q.2YX<V102P$"% ,4
M"  :2)-2XZ:3Y8P&  !)1P  %0              @ '^,P  ;61X9RTR,#(Q
M,#0Q.5]L86(N>&UL4$L! A0#%     @ &DB34@4U-<;1!   PRP  !4
M         ( !O3H  &UD>&<M,C R,3 T,3E?<')E+GAM;%!+!08     !0 %
+ #X!  #!/P     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
